Contineum Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $19.3M | $18.9M | $414.0K | $2.2M |
| FY2024 | $-32.8M | $-33.4M | $514.0K | $6.8M |
| FY2025 | $-55.3M | $-55.5M | $231.0K | $10.0M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $19.3M | $18.9M | $414.0K | $2.2M |
| FY2024 | $-32.8M | $-33.4M | $514.0K | $6.8M |
| FY2025 | $-55.3M | $-55.5M | $231.0K | $10.0M |